A Study of SGN-EGFRd2 in Advanced Solid Tumors
- Conditions
- Interventions
- Registration Number
- NCT05983133
- Lead Sponsor
- Seagen Inc.
- Brief Summary
This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic).
...
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 275
-
Tumor types:
-
For Part A: Participants must have disease that is relapsed, refractory, or be intolerant to standard of care therapies, and in the judgement of the investigator must have no appropriate standard therapy available at the time of enrollment. Participants must have histologically- or cytologically confirmed metastatic or unresectable solid malignancy from one of the following tumor types:
- Colorectal cancer (CRC)
- Non-small cell lung cancer (NSCLC)
- Head and neck squamous cell cancer (HNSCC)
-
For Part B: Participants must have disease that is relapsed, refractory, or be intolerant to standard of care therapies, and in the judgement of the investigator must have no appropriate standard therapy available at the time of enrollment.
- The tumor type(s) to be enrolled in dose optimization will be identified by the sponsor from among those specified in Part A.
-
For Part C: Participants must have disease that is relapsed or refractory or be intolerant to standard of care therapies as specified below, unless contraindicated:
-
CRC
- Participants must have unresectable locally advanced or metastatic CRC.
- Prior therapy: Participants must have received prior fluoropyrimidine, oxaliplatin and irinotecan. Participants with defective mismatch repair and microsatellite instability high (dMMR/MSI-H) should have received prior treatment with pembrolizumab, a nivolumab-containing regimen, or other available anti-PD-1 (programmed cell death protein 1) or anti PD L1 (programmed cell death 1 ligand) agents.
-
NSCLC
- Participants must have unresectable locally advanced or metastatic NSCLC.
- Prior therapy: Participants must have received platinum-based therapy and at least 1 PD-1/PD-L1 inhibitor. These agents may have been administered either as single agents or in combination. Participants with an activating mutation or rearrangement (eg, EGFR, anaplastic lymphoma kinase [ALK], etc.) must have received available targeted agents if eligible by biomarker status and local standard of care.
-
HNSCC
- Participants must have unresectable locally advanced or metastatic HNSCC
- Prior therapy: Participants must have received platinum-based therapy and a PD-1/PD-L1 inhibitor, if eligible by biomarker status and local standard of care. These agents may have been administered either as single agents or in combination.
-
Pancreatic ductal adenocarcinoma (PDAC)
- Participants must have unresectable locally advanced or metastatic PDAC.
- Prior therapy: Participants must have received gemcitabine- or FOLFIRINOX-based therapy.
-
-
-
Participants should provide archival tumor tissue if available and also agree to biopsies, if medically feasible
-
An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
-
Measurable disease at baseline per RECIST 1.1 criteria.
-
History of another malignancy within 3 years before the first dose of study treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death
-
Known active central nervous system metastases or leptomeningeal disease. Participants with previously treated brain metastases may participate provided they are
- clinically stable for at least 4 weeks prior to study entry after brain metastases treatment,
- they have no new or enlarging brain metastases,
- and are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug.
-
Treatment with an aminobisphosphonate IV (eg ibandronate, pamidronate, zoledronate, etc.) within 4 weeks of the first dose of study treatment.
-
Participants with history of thromboembolic phenomena (pulmonary embolism, deep vein thrombosis, stroke, or ischemic attack) within 6 months prior to the first dose of study drug, currently receiving chronic anticoagulation therapy, or with contraindication to treatment for thromboembolism prophylaxis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description SGN-EGFRd2 SGN-EGFRd2 SGN-EGFRd2 monotherapy
- Primary Outcome Measures
Name Time Method Number of participants with dose limiting toxicities (DLTs) Up to 35 days Number of participants with laboratory abnormalities Through 30-37 days after last study treatment, up to approximately 1 year Number of participants with adverse events (AEs) Through 90 days after last study treatment, up to approximately 1 year An AE is any untoward medical occurrence in a clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention
Number of participants with DLTs by dose level Up to 35 days
- Secondary Outcome Measures
Name Time Method Number of participants with antidrug antibodies (ADAs) Through 30-37 days after last study treatment, up to approximately 1 year To be summarized using descriptive statistics
PK parameter - Time to maximum concentration (Tmax) Through 30-37 days after last study treatment, up to approximately 1 year To be summarized using descriptive statistics
PK parameter - Apparent terminal half-life (t1/2) Through 30-37 days after last study treatment, up to approximately 1 year To be summarized using descriptive statistics
Pharmacokinetic (PK) parameter - Area under the curve (AUC) Through 30-37 days after last study treatment, up to approximately 1 year To be summarized using descriptive statistics
PK parameter - Trough concentration (Ctrough) Through 30-37 days after last study treatment, up to approximately 1 year To be summarized using descriptive statistics
Progression-free survival (PFS) Up to approximately 2 years PFS is defined as the time from start of SGN-EGFRd2 to first documentation of disease progression or death due to any cause, whichever comes first
PK parameter - Maximum concentration (Cmax) Through 30-37 days after last study treatment, up to approximately 1 year To be summarized using descriptive statistics
Objective response rate (ORR) Up to approximately 2 years ORR is defined as the proportion of participants with an objective response per Response Evaluation in Solid Tumors (RECIST) 1.1 per investigator. A participant is determined to have an objective response if, based on RECIST 1.1, they achieve a complete response (CR) or partial response (PR) after initiation of treatment and at or prior to the EOT disease as...
Duration of response (DOR) Up to approximately 2 years DOR is defined as the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per RECIST 1.1 or to death due to any cause, whichever comes first
Overall survival (OS) Up to approximately 3 years OS is defined as the time from start of SGN-EGFRd2 to date of death due to any cause
Trial Locations
- Locations (13)
UCLA Department of Medicine - Hematology & Oncology
🇺🇸Santa Monica, California, United States
H. Lee Moffitt Cancer Center and Research Institute
🇺🇸Tampa, Florida, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Institute / Wayne State University
🇺🇸Detroit, Michigan, United States
Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Wake Forest Baptist Medical Center / Wake Forest University
🇺🇸Winston-Salem, North Carolina, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
MD Anderson Cancer Center / University of Texas
🇺🇸Houston, Texas, United States
Huntsman Cancer Institute/University of Utah
🇺🇸Salt Lake City, Utah, United States
University College London Hospitals NHS Foundation Trust
🇬🇧London, Other, United Kingdom
The Christie NHS Foundation Trust
🇬🇧Manchester, Other, United Kingdom